IMPERATIVE NEED TO IMPROVE OUTCOMES FOR WOMEN DIAGNOSED WITH OVARIAN CANCER. ANZGOG Chair gives stark assessment on late diagnosis, limited treatment options and significantly low survival rates
With
Professor Clare Scott, Chair
Australia New Zealand Gynaecological Oncology Group (ANZGOG) &
Clinician Scientist
WEHI The Walter and Eliza Hall Institute of Medical Research &
Medical Oncologist, Peter MacCallum Cancer Centre, The Royal Women’s Hospital and The Royal Melbourne Hospital
Australian Health Journal Talk
Filmed Online | April 2025
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
ANZGOG’s values—excellence, impact, equity, collaboration, and openness—reflect the organisation’s dedication to transformative cancer research. Its strategic plan is designed around four comprehensive goals, aiming to initiate innovative, practice-changing gynaecological cancer research. This not only expands the reach of impactful studies but also ensures that research directly benefits the community, ultimately improving the lives of countless women affected by these cancers.
Ovarian cancer, a complex and diverse group of diseases, poses significant challenges in diagnosis and treatment. While high-grade serous ovarian cancer is often highlighted, other rare types also demand critical attention. With projections indicating over 1,800 Australian women will be diagnosed by 2025, and a startling survival rate of just under 50%, Professor Scott talks of the need to rally together to confront this pressing public health issue. Tragically, two-thirds of cases are diagnosed at an advanced stage, diminishing survival prospects further. As of now, around 5,300 Australian women live with ovarian cancer, facing ongoing challenges that necessitate urgent action and support.
In this Australian Health Journal Talk, Professor Scott talks in detail about the following –
- The incidence of ovarian cancer in Australian women and mortality statistics around advanced stage diagnosis
- The symptoms and why they get dismissed or misdiagnosed
- The challenges in access to screening, treatment and funding for research
She also delivers a message to the medical community and the Australian Government.
Source: Generative AI on transcript
-
Metabolic health expert talks about healthy ageing
David Beard is a highly experienced Exercise Physiologist with a specialisation in metabolic health and healthy aging. He has spent over 40 years in this profession, even before exercise physiology was formally recognised as a discipline. His extensive background includes over a decade of working in aged care and a strong focus on adult health and fitness. David has authored a book on healthy aging and dedicated the last 10 to 12 years to advancing his expertise in metabolic health issues such as diabetes, weight loss, and inflammatory conditions. He is a co-owner of HFRC in Nedlands, Western Australia, where he has worked for nearly a decade.
-
FULL FEATURE Consumers and communities as agents of health care change and improvement
Policymakers, health administrators and clinicians must learn and embrace new ways to harness the transformative role consumers, community members and carers can play. Conversely, consumers and communities need support, capability and capacity to engage as equals in policy, research, program and service design. This is necessary if are to be less technocratic and realise the vision where all members of society can live the best life possible.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
